NYSE:CRY - Cryolife Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $28.58 -0.49 (-1.69 %) (As of 12/17/2018 01:39 AM ET)Previous Close$28.58Today's Range$28.3614 - $29.1252-Week Range$16.80 - $36.05Volume95,046 shsAverage Volume124,308 shsMarket Capitalization$1.06 billionP/E Ratio71.45Dividend YieldN/ABeta0.51 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft systems for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G is a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia. Receive CRY News and Ratings via Email Sign-up to receive the latest news and ratings for CRY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:CRY Previous Symbol CUSIP22890310 Webwww.cryolife.com Phone770-419-3355 Debt Debt-to-Equity Ratio0.78 Current Ratio5.66 Quick Ratio4.16 Price-To-Earnings Trailing P/E Ratio71.45 Forward P/E Ratio86.61 P/E GrowthN/A Sales & Book Value Annual Sales$189.70 million Price / Sales5.57 Cash Flow$0.7045 per share Price / Cash Flow40.57 Book Value$8.28 per share Price / Book3.45 Profitability EPS (Most Recent Fiscal Year)$0.40 Net Income$3.70 million Net Margins-2.05% Return on Equity4.25% Return on Assets2.03% Miscellaneous Employees1,000 Outstanding Shares36,970,000Market Cap$1.06 billion OptionableOptionable Cryolife (NYSE:CRY) Frequently Asked Questions What is Cryolife's stock symbol? Cryolife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY." How were Cryolife's earnings last quarter? Cryolife Inc (NYSE:CRY) released its quarterly earnings data on Wednesday, October, 31st. The medical equipment provider reported $0.08 EPS for the quarter, beating the consensus estimate of $0.07 by $0.01. The medical equipment provider earned $64.60 million during the quarter, compared to the consensus estimate of $64.57 million. Cryolife had a positive return on equity of 4.25% and a negative net margin of 2.05%. The firm's revenue for the quarter was up 46.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.08 EPS. View Cryolife's Earnings History. When is Cryolife's next earnings date? Cryolife is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Cryolife. What guidance has Cryolife issued on next quarter's earnings? Cryolife updated its FY18 earnings guidance on Wednesday, October, 31st. The company provided EPS guidance of $0.30-0.33 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.32. The company issued revenue guidance of $261.5-262.5 million, compared to the consensus revenue estimate of $260.68 million.Cryolife also updated its FY 2018 guidance to $0.30-0.33 EPS. What price target have analysts set for CRY? 2 Wall Street analysts have issued 12 month target prices for Cryolife's shares. Their predictions range from $32.00 to $36.00. On average, they expect Cryolife's share price to reach $34.00 in the next twelve months. This suggests a possible upside of 19.0% from the stock's current price. View Analyst Price Targets for Cryolife. What is the consensus analysts' recommendation for Cryolife? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cryolife in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cryolife. Has Cryolife been receiving favorable news coverage? News headlines about CRY stock have trended somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cryolife earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. Who are some of Cryolife's key competitors? Some companies that are related to Cryolife include Integra Lifesciences (IART), Novocure (NVCR), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), K2M Group (KTWO), Nevro (NVRO), Luminex (LMNX), AtriCure (ATRC) and Orthofix Medical (OFIX). Who are Cryolife's key executives? Cryolife's management team includes the folowing people: Mr. James Patrick MacKin, Chairman, Pres & CEO (Age 51)Mr. David Ashley Lee, Exec. VP, COO & CFO (Age 53)Ms. Jean F. Holloway, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 61)Mr. John E. Davis, Sr. VP of Global Sales & Marketing (Age 53)Ms. Amy D. Horton, VP & Chief Accounting Officer (Age 48) Who are Cryolife's major shareholders? Cryolife's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.63%), Capital Research Global Investors (7.68%), Vanguard Group Inc (5.46%), Vanguard Group Inc. (5.46%), Dimensional Fund Advisors LP (5.41%) and Morgan Stanley (4.66%). Company insiders that own Cryolife stock include Amy Horton, C Elkins Ronald, David Ashley Lee, David C Gale, Harvey Morgan, James Benson, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View Institutional Ownership Trends for Cryolife. Which institutional investors are selling Cryolife stock? CRY stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Renaissance Technologies LLC, Macquarie Group Ltd., Monarch Partners Asset Management LLC, Royce & Associates LP, Penn Capital Management Co. Inc., William Blair Investment Management LLC and JPMorgan Chase & Co.. Company insiders that have sold Cryolife company stock in the last year include Amy Horton, C Elkins Ronald, David Ashley Lee, Harvey Morgan, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View Insider Buying and Selling for Cryolife. Which institutional investors are buying Cryolife stock? CRY stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Castleark Management LLC, Capital International Investors, EAM Investors LLC, Vanguard Group Inc, Vanguard Group Inc., Bank of New York Mellon Corp and Capital Guardian Trust Co.. View Insider Buying and Selling for Cryolife. How do I buy shares of Cryolife? Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cryolife's stock price today? One share of CRY stock can currently be purchased for approximately $28.58. How big of a company is Cryolife? Cryolife has a market capitalization of $1.06 billion and generates $189.70 million in revenue each year. The medical equipment provider earns $3.70 million in net income (profit) each year or $0.40 on an earnings per share basis. Cryolife employs 1,000 workers across the globe. What is Cryolife's official website? The official website for Cryolife is http://www.cryolife.com. How can I contact Cryolife? Cryolife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider can be reached via phone at 770-419-3355 or via email at [email protected] MarketBeat Community Rating for Cryolife (NYSE CRY)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 258 (Vote Outperform)Underperform Votes: 184 (Vote Underperform)Total Votes: 442MarketBeat's community ratings are surveys of what our community members think about Cryolife and other stocks. Vote "Outperform" if you believe CRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/17/2018 by MarketBeat.com StaffFeatured Article: What is the LIBOR?